Beam Therapeutics Inc (BEAM) — Cash Flow Reinvestment Rate

Latest as of December 2023: 0.75x

Beam Therapeutics Inc (BEAM) has a Cash Flow Reinvestment Rate of 0.75x as of December 2023, reinvesting $101.69 Million (capex $3.59 Million plus investments $98.10 Million) from operating cash flow of $135.07 Million. See cash generation quality of Beam Therapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.75x
(Capex + Investments) / Operating CF

Total Reinvested

$101.69 Million
Capex + Investments

Operating Cash Flow

$135.07 Million
USD

Capital Expenditures

$3.59 Million
USD

Beam Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)

Historical reinvestment intensity for Beam Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see Beam Therapeutics Inc (BEAM) cash flow conversion.

Annual Cash Flow Reinvestment Rate for Beam Therapeutics Inc (2022–2022)

Year-by-year capital reinvestment analysis for Beam Therapeutics Inc. See financial agility of Beam Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2022 22.65x $510.29 Million $22.53 Million $48.95 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow